RXRX → $2.70 by Aug 24, 2026.

**Ticker:** RXRX **Company:** Recursion Pharmaceuticals **Current area:** Low-$3s **My bias:** Bearish short-term / tactical short **Primary downside target:** $2.70 **Stretch target:** $2.50–$2.60 **Invalidation:** Reclaim and hold above $3.25–$3.35 # Thesis I’m still looking at RXRX as a tactical short candidate. The setup has not changed much from last week: the stock is trading near fresh 52-week lows, the broader technical trend remains broken, and the company is still a cash-burning clinical-stage biotech being valued mostly on future pipeline potential and …